Eisai ramps up Indian production; India court takes aim at Ranbaxy; Orchid, Hospira deal about done;

> Japan's Eisai intends to nearly triple production to 2 billion tablets at its plant in Vizag, India. Report

> The FDA has added two Chinese drug manufacturing facilities to its list of banned plants. Alerts

> India's Supreme Court ruled in favor of a public interest investigation into whether Ranbaxy Laboratories supplied adulterated drugs in the country. Report

> Ranbaxy Laboratories insists the drugs it sells in India are safe and effective. Story

> Optel Visions is expanding its inspection systems offerings. Release

And Finally... Orchid Chemicals and Pharmaceuticals has gotten approval to complete the sale of its penicillin and penems active pharmaceutical ingredient business to Hospira ($HSP) as part of Orchid's debt restructuring plan. Report